These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 8423625)

  • 41. [Study of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 for metastatic renal cell carcinoma. I. Generation of LAK cells by incubation in serum-free medium].
    Nomura K; Fujioka T
    Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):822-30. PubMed ID: 8320887
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Lysis of autologous tumor cells by peripheral blood lymphocytes treated with IFN-alpha in patients with renal cell carcinoma].
    Kubota S
    Nihon Hinyokika Gakkai Zasshi; 1992 Nov; 83(11):1781-8. PubMed ID: 1479751
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nonviral interferon alpha gene therapy inhibits growth of established tumors by eliciting a systemic immune response.
    Coleman M; Muller S; Quezada A; Mendiratta SK; Wang J; Thull NM; Bishop J; Matar M; Mester J; Pericle F
    Hum Gene Ther; 1998 Oct; 9(15):2223-30. PubMed ID: 9794206
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increase in the capability of interleukin 2 gene-transduced renal cell carcinoma cells to induce cytotoxic lymphocytes.
    Itoh K; Umezu Y; Morita T; Saya H; Seito D; Augustus LB; Nakao M; Sakata M; Miyajima J; Masuoka K
    Kurume Med J; 1994; 41(2):53-63. PubMed ID: 7967440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytotoxic in vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy. Effects of activation with recombinant interleukin-2.
    Feruglio C; Zambello R; Trentin L; Bulian P; Franceschi T; Cetto GL; Semenzato G
    Cancer; 1992 May; 69(10):2525-31. PubMed ID: 1568175
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes.
    Arienti F; Sulé-Suso J; Melani C; Maccalli C; Belli F; Illeni MT; Anichini A; Cascinelli N; Colombo MP; Parmiani G
    Hum Gene Ther; 1994 Sep; 5(9):1139-50. PubMed ID: 7833372
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
    Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
    Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The prognostic significance of immune changes in patients with renal cancer and melanoma treated with interferon-alpha 2b.
    Tsavaris N; Baxevanis K; Kosmidis P; Papamichael M
    Tumour Biol; 1995; 16(6):365-73. PubMed ID: 7569683
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
    Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
    Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
    Kudo-Saito C; Wansley EK; Gruys ME; Wiltrout R; Schlom J; Hodge JW
    Clin Cancer Res; 2007 Mar; 13(6):1936-46. PubMed ID: 17363550
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma.
    Hillman GG; Slos P; Wang Y; Wright JL; Layer A; De Meyer M; Yudelev M; Che M; Forman JD
    Cancer Gene Ther; 2004 Jan; 11(1):61-72. PubMed ID: 14681727
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-alpha and interleukin-2.
    Sonouchi K; Hamilton TA; Tannenbaum CS; Tubbs RR; Bukowski R; Finke JH
    Am J Pathol; 1994 Apr; 144(4):747-55. PubMed ID: 8160774
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
    Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
    Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of a novel interferon-α2b gene construct with a repetitive hypoxia-inducible factor binding site and its suppressive effects on human renal cell carcinoma cell lines in vitro.
    Fukui N; Kageyama Y; Higashi Y; Kihara K; Kizaka-Kondoh S; Hiraoka M; Shinojima T; Suzuki K; Oya M
    Int J Clin Oncol; 2014; 19(3):497-504. PubMed ID: 23739923
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma.
    Amato RJ; Shetty A; Lu Y; Ellis PR; Mohlere V; Carnahan N; Low PS
    J Immunother; 2014 May; 37(4):237-44. PubMed ID: 24714357
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Significant antitumoral activity of cationic multilamellar liposomes containing human IFN-beta gene against human renal cell carcinoma.
    Nakanishi H; Mizutani Y; Kawauchi A; Ukimura O; Shiraishi T; Hatano M; Mizuno M; Yoshida J; Miki T
    Clin Cancer Res; 2003 Mar; 9(3):1129-35. PubMed ID: 12631618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.